Sweeneys to make room for new leadership at Dorland

Share this article:
L-r: Rich Minoff will become president/CEO of Dorland Global, succeeding Rita and Harry Sweeney
L-r: Rich Minoff will become president/CEO of Dorland Global, succeeding Rita and Harry Sweeney
Harry and Rita Sweeney, the couple who founded medical communications firm Dorland Global 35 years ago, will leave their executive positions as of January 1st, 2008, the agency announced yesterday. Assuming the role of CEO and president will be Rich Minoff, a five-year veteran who helped orchestrate the $20.7-million sale of Dorland to Huntsworth PLC earlier this year.
The 125-person agency maintains two business units, advertising and PR. Clients include Johnson & Johnson, Roche and Boston Scientific.
“Harry and I are confident that [Minoff] will not only continue to service our clients and employees in the manner that Dorland Global is known for, but will also take the agency in a new direction with the Huntsworth organization,” said Rita Sweeney, who had served as president, chief operating officer. The COO position will be eliminated. Her husband is stepping down as CEO.
Minoff joined the agency in 2002 as president of Dorland Global Health Communications, a branding and marketing division which has grown 47% per year under his watch. In addition, he has 14 years of senior managerial experience at various agencies, along with 12 years on the client side working for GlaxoSmithKline and Wyeth.
Thanks to the March purchase, Dorland Global's two main business units, Dorland Global Health Communications and Dorland Global Public Relations, now serve as the US affiliate of the UK-based Huntsworth health division.
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.